E-coli L-asparaginase
Phase 2Protein / enzyme
E-coli L-asparaginase is one of 43 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
163 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyPhase 3
Adriamycin
PfizerPhase 3
Oncaspar
SServier
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Fludara
SanofiPhase 3
Medrol
PfizerPhase 3
Iclusig
TakedaPhase 3
Cellcept
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia2 trials
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
Completed·—·Phase 2·NCT00136435·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for E-coli L-asparaginase. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details